CN103933109A - Method for treating animal escherichia coli infected diseases - Google Patents
Method for treating animal escherichia coli infected diseases Download PDFInfo
- Publication number
- CN103933109A CN103933109A CN201410150094.0A CN201410150094A CN103933109A CN 103933109 A CN103933109 A CN 103933109A CN 201410150094 A CN201410150094 A CN 201410150094A CN 103933109 A CN103933109 A CN 103933109A
- Authority
- CN
- China
- Prior art keywords
- compound medicine
- treatment
- herba speranskiae
- speranskiae tuberculatae
- antimicrobial drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to a method for treating animal escherichia coli infected diseases. The method comprises the following steps: mixing phryma leptostachya and an antibacterial medicament for treating animal escherichia coli infection at a weight ratio of (3-30):(5-200) to obtain a compound medicament containing the phryma leptostachya, adding the compound medicament into an animal feed according to the adding quantity of 0.1-7g/kg feed, and continuously feeding animals for 3-7 days. By adopting the method, the tolerance of bacteria to the antibacterial medicament can be effectively reversed, so that the treatment effect of the antibacterial medicament is improved, the medicament cost and the medicament residue are greatly reduced, high economic benefits are created for farmers, and the food safety of human beings is guaranteed.
Description
Technical field
The invention belongs to poultry coli-infection treatment technology field, relate in particular to a kind of method for the treatment of poultry coli-infection disease.
Background technology
Escherichia coli are common conditioned pathogens, also be normal a kind of disease of sending out, its multiple location severe infections such as chicken acute sepsis, peritonitis, hepatitis, pneumonia, enteritis of can formerly having carried out the coffin upon burial, also can secondary or mixed sending out in virosis, causes huge economic loss to aquaculture.The beta-lactam lopps antibiotic such as amoxicillin, ampicillin, ceftiofur, ceftriaxone, amoxicillin/clavulanate, ampicillin/sulbactam are the conventional important drugs of this disease of control, along with cultivation scale intensive degree is more and more large, medication is more and more spread unchecked, its Resistant strain is more and more many, also more about the report of Drug Resistance of E. coli.Studies confirm that, one of main mechanism of drug resistance is to produce beta-lactamase, especially extended spectrumβ-lactamase (Extended-Spectrum β-lactamase, ESBLs), this enzyme can be hydrolyzed beta-lactam nucleus more by force and rapidly, makes this class antibiotic lose antibacterial activity.ESBLs is the main enzyme type of beta-lactamase, and it is not only to cephalo three generations and aztreonam drug resistance, and aminoglycoside, quinolones and sulfonamides are to crossing drug resistant, only to carbapenems, a mould alkene class medicaments insensitive.Many documents reported colibacillary multi-drug resistant with produce ESBLs have substantial connection, both at home and abroad to comparatively pay close attention to.The detection, extraction, enzyme that inventor has carried out food animal source pathogenic bacterium ESBLs recently presses down the researchs such as enzyme protection effect to antibiotic percent hydrolysis and sulbactam, Tazobactam Sodium and Chinese medicine; to part ESBLs, colibacillary drug sensitive test shows, its multidrug resistant rate is apparently higher than non-ESBLs bacterial strain.In addition, result also shows to produce ESBLs bacterial strain not only to the serious drug resistance of the third generation cephalosporins such as ceftiofur, and also to multiple antimicrobial drug drug resistance such as fluoroquinolones, aminoglycoside and sulfonamides, fosfomycin etc., is serious multidrug resistant.Inventor, producing the escherichia coli that are separated to tolerate P-levels mycin product fosA3 drug resistant gene in ESBLs bacterial strain, has more strengthened the drug resistance of antibacterial.Colibacillary drug resistance causes raiser's drug cost to increase, and treatment extends the course for the treatment of, and mortality of livestock increases, and brings larger economic loss to production, and increases poultry drug residue risk.Therefore, needing a kind of method that can treat preferably coli-infection disease in actual production badly, shorten treatment course for the treatment of, reduce mortality rate, reduce economic loss and reduce drug residue, is that raiser creates higher economic benefit, also ensures that the mankind's is healthy and safe.
Summary of the invention
The technical problem to be solved in the present invention is to provide a kind of method for the treatment of poultry coli-infection disease, can kill quickly antibacterial, overcomes large, the residual height of weak curative effect, consumption and the high defect of cost that antimicrobial drug treatment causes due to drug resistance problem.
For solving above technical problem, the present invention is by the following technical solutions: a kind of method for the treatment of poultry coli-infection disease, Herba speranskiae tuberculatae is mixed according to the part by weight of 3-30:5-200 with the antimicrobial drug for the treatment of poultry coli-infection, obtain the compound medicine containing Herba speranskiae tuberculatae, this compound medicine is added in animal and fowl fodder and fed according to the addition of 0.1-7g/kg feedstuff, use continuously 3-7 days.
Antimicrobial drug is the one in beta-lactam, fluoroquinolones, aminoglycoside, carbadox class, polypeptide class, amide alcohols or valnemulin hydrochloride.
Beta-lactam antimicrobial drug is amoxicillin, ceftriaxone sodium or ceftiofur sodium; Fluoroquinolone antibacterial agent is norfloxacin; Aminoglycoside antimicrobial drug is amikacin; Carbadox class antimicrobial drug is LIJUNJING; Amide alcohols is florfenicol; Polypeptide class antimicrobial drug is colistin.
Further, described compound medicine comprises the raw material of following weight portion: amoxicillin 3-20 part and Herba speranskiae tuberculatae 40-180 part, or norfloxacin 3-25 part and Herba speranskiae tuberculatae 30-190 part, or amikacin 5-30 part and Herba speranskiae tuberculatae 10-160 part, or LIJUNJING 3-20 part and Herba speranskiae tuberculatae 10-180 part, or colistin 3-30 part and Herba speranskiae tuberculatae 15-170 part, or florfenicol 5-30 part and Herba speranskiae tuberculatae 10-170 part, or valnemulin hydrochloride 7-30 part and Herba speranskiae tuberculatae 10-170 part.
The dosage form of this compound medicine is prepared into powder, tablet, oral liquid or granule.
The preparation method of the compound medicine of above-mentioned treatment poultry coli-infection disease, pulverized 60 mesh sieves by Herba speranskiae tuberculatae, then mixed with pulverous antimicrobial drug, was prepared into according to a conventional method powder, tablet, oral liquid or granule.
The drug resistance problem existing for current poultry coli-infection, inventor utilizes Guangxi Special Traditional Chinese Medicine Herba speranskiae tuberculatae and antimicrobial drug composition compound medicine.Studies have shown that, in antimicrobial drug, add after Herba speranskiae tuberculatae, can reverse the drug resistance of bacteria medicine, thereby improve the therapeutic effect of antimicrobial drug.According to a conventional method this compound medicine is made to powder, tablet, oral liquid or granule, add in animal and fowl fodder and feed according to the addition of 0.1-7g principal agent/kg feedstuff, can significantly reduce drug cost and drug residue, for raiser creates higher economic benefit, also guarantee food safety simultaneously.
Detailed description of the invention
One, the drug resistance inversion effect research of Herba speranskiae tuberculatae to antimicrobial drug
Antimicrobial drug itself has the colibacillary effect for the treatment of, but because the escherichia coli that produce ESBLs drug resistant gene have stronger drug resistance, causes antimicrobial drug not show good therapeutic effect in normal using dosage situation.
In order to verify the drug resistance inversion effect of Herba speranskiae tuberculatae to antimicrobial drug, on 96 orifice plates, adopt microtest tube doubling dilution, first measure minimal inhibitory concentration and the subinhibitory concentration of Herba speranskiae tuberculatae to product ESBLs and fosA3 drug resistant gene e. coli strains of the e. coli strains of antimicrobial drug to product ESBLs and fosA3 drug resistant gene, then in culture medium, added the Herba speranskiae tuberculatae of subinhibitory concentration to reuse the minimal inhibitory concentration of microtest tube doubling dilution cultivation mensuration antimicrobial drug; Utilize continuous passage method in the culture medium that is added with same subinhibitory concentration Herba speranskiae tuberculatae and same concentration antimicrobial drug to producing the cultivation of going down to posterity of ESBLs and fosA3 drug resistant gene e. coli strains, until the antimicrobial drug minimal inhibitory concentration observing diminishes more than 4 times compared with before going down to posterity, can be judged as Herba speranskiae tuberculatae has drug resistance inversion effect to antibacterial medical instrument.Result of the test statistics is as shown in table 1:
Table 1 subinhibitory concentration (0.25g/mL) Herba speranskiae tuberculatae goes down to posterity and causes the variation (μ g/mL) of producing ESBLs and fosA3 escherichia coli Western medicine MIC.
As seen from the above table, antimicrobial drug all reduces more than 4 times the colibacillary minimal inhibitory concentration of drug resistance, can judge that Herba speranskiae tuberculatae has drug resistance inversion effect to producing ESBLs and fosA3 drug resistant gene escherichia coli.
Two, application example of the present invention
Prepare in accordance with the following methods compound medicine 1-compound medicine 20: Herba speranskiae tuberculatae was pulverized after 60 mesh sieves, as basic material, again with pulverous antimicrobial drug by weight ratio put into blender and mix, according to a conventional method, compound medicine 2,3,6,9,15 and 19 is prepared into powder; Compound medicine 1,5,10,16 and 18 is prepared into tablet, and compound medicine 7,11,13 and 17 is prepared into oral liquid; Compound medicine 4,8,12,14 and 20 is prepared into granule.
Formula and the product of table 2 compound medicine 1-20
Inventor obtains compound medicine product by above-mentioned compound medicine and has carried out following experiment:
1, the efficacy experiment of the compound medicine product of compound medicine 1-4 gained to chicken escherichia coil disease
Clinical symptoms: Guangxi Yulin chicken house, 25 Day-old Broiler Chickens, there is fragmentary death in chicken group, cuts open the indivedual chickens of inspection and occur the pathological change of bag pericardium liver, typical bacillus coli feature.
Laboratory diagnosis: get pathologic liver and dye sheet, Gram’s staining, micro-Microscopic observation, the gram negative bacilli of red color visible; Tentatively be judged as bacillus coli.Cultivate by escherichia coli, biochemical test is differentiated, judges that chicken infects for bacillus coli, and pcr amplification, proves to produce the ESBLs drug resistant gene that has TEM type.
Test therapeutic regimen: morbidity chicken group is divided into 6 groups of administrations, use compound medicine 1 according to the addition administration of 3.8g/kg feedstuff for first group, use compound medicine 2 according to the addition administration of 2g/kg feedstuff for second group, use compound medicine 3 according to the addition administration of 0.8g/kg feedstuff for the 3rd group, use compound medicine 4 according to the addition administration of 2g/kg feedstuff for the 4th group; The 5th group with amoxicillin powder according to the addition administration of 0.2g/kg feedstuff, the 6th group with the thick powder of Herba speranskiae tuberculatae according to the addition administration of 3.7g/kg feedstuff; Above six groups of therapeutic regimens all continue to use 5 days.
Effect feedback: after the chicken group medication of first group to the 4th group, sick chicken feed intake rises, and no longer occurs dead chicken, continues to use 3 days, and chicken group be almost recovered; The chicken group medication of the 5th group is after 2 days, and chicken group majority is still unhealthy, still has indivedual chicken deaths, continues to use 3 days, and chicken death phenomenon is not still effectively controlled; The chicken group medication of the 6th group is after 2 days, and chicken group does not have too large remarkable improvement, continues to use 3 days, and chicken death phenomenon is not still effectively controlled.Visible, the compound medicine curative effect that contains Herba speranskiae tuberculatae is better than folk prescription.
2, the efficacy experiment of the meat-type duck diarrhoea of the compound medicine product of compound medicine 5-8 gained to 20 ages in days
Clinical symptoms: duck field, Nanning, 20 age in days meat-type duck, duck group draws watery stools, has obvious indigested feedstuff in feces.A duck group material feeding is not but long, and the serious duck appearance foot gradually of suffering from diarrhoea is individually soft slowly dead.
Cut open inspection pathological changes: the duck that dies of illness dehydration is more serious, indivedual ducks are still very large, duck liver enlargement, hyperemia, and adularescent film on the liver of part duck, air bag muddiness, tentative diagnosis is escherichia coli or duck oromeningitis.
Test therapeutic regimen: morbidity duck group divides six groups of administrations, use compound medicine 5 according to the addition administration of 2g/kg feedstuff for first group, use compound medicine 6 according to the addition administration of 1g/kg feedstuff for second group, use compound medicine 7 according to the addition administration of 1g/kg feedstuff for the 3rd group, use compound medicine 8 according to the addition administration of 0.2g/kg feedstuff for the 4th group; The 5th group with norfloxacin powder according to the addition administration of 0.15g/kg feedstuff, the 6th group with the thick powder of Herba speranskiae tuberculatae according to the addition administration of 2.0g/kg feedstuff; Above six groups of therapeutic regimens all continue to use 5 days.
Result of use feedback: first group to the 4th group medication is after 2 days, and sick duck is no longer drawn watery stools, feces is shaped, and no longer occurs dead duck, continues to use 3 days, and duck group be almost recovered; The 5th group of medication is after 2 days, and duck group DeGrain, much still draws watery stools, contain indigested feedstuff, continue to use 3 days, some improvement a little, but not good thorough, rare watery stools still occurs, raiser cannot drug withdrawal to these two groups of ducks, have to use the compound medicine of compound medicine 6 gained instead, continue to use 2 days, just be almost recovered, re-use 1 day, feces all transfers to normally; The 6th group of medication is after 2 days, and duck does not have too large remarkable improvement, continues to use 3 days, and the duck phenomena of mortality are not still effectively controlled.Visible, the compound medicine that contains Herba speranskiae tuberculatae is better than folk prescription to the curative effect of duck diarrhoea.
3, the efficacy experiment of the meat-type duck diarrhoea of the compound medicine product of compound medicine 9-12 gained to 30 ages in days
Clinical symptoms: Guangxi Qinzhou duck field, 30 age in days meat-type duck, duck group draws watery stools, has obvious indigested feedstuff in feces.Indivedual serious duck appearance feet gradually of suffering from diarrhoea are soft slowly dead.
Cut open inspection pathological changes: the duck that dies of illness dehydration is more serious, indivedual ducks are still very large, duck liver enlargement, hyperemia, and adularescent film on the liver of part duck, air bag muddiness, tentative diagnosis is escherichia coli or duck oromeningitis.
Test therapeutic regimen: morbidity duck group divides six groups of administrations, use compound medicine 9 according to the addition administration of 1.5g/kg feedstuff for first group, use compound medicine 10 according to the addition administration of 0.2g/kg feedstuff for second group, use compound medicine 11 according to the addition administration of 2g/kg feedstuff for the 3rd group, use compound medicine 12 according to the addition administration of 0.7g/kg feedstuff for the 4th group; The 5th group with amikacin powder according to the addition administration of 0.2g/kg feedstuff, the 6th group with the thick powder of Herba speranskiae tuberculatae according to the addition administration of 2.0g/kg feedstuff; Above six groups of therapeutic regimens all continue to use 5 days.
Result of use feedback: first group to the 4th group medication is after 3 days, and sick duck is no longer drawn watery stools, feces is shaped, and no longer occurs dead duck, continues to use 2 days, and duck group be almost recovered; The 5th group of medication is after 3 days, duck group DeGrain, much still draw watery stools, contain indigested feedstuff, continue to use 2 days, some improvement a little, but thoroughly not good, rare watery stools still occurs, raiser uses the compound medicine of compound medicine 9 gained instead, continue to use 3 days, feces all transfers to normally; The 6th group of medication is after 3 days, and duck does not have too large remarkable improvement, continues to use 2 days, and the duck phenomena of mortality are not still effectively controlled.Visible, the compound medicine that contains Herba speranskiae tuberculatae is better than folk prescription to the curative effect of duck diarrhoea.
4, the efficacy experiment of the piglet diarrhea of the compound medicine product of compound medicine 13-16 gained to 45 ages in days
Clinical symptoms: pig farm, Nanning, 45 age in days piglets, this swinery after wean is turn-taked, starts to occur diarrhoea, draws watery stools, feces contains indigested feedstuff, pig material feeding but be exactly not grow, indivedual serious diarrhea of pigs dehydrations are dead, do not occur symptoms of emesis, raiser uses multi-medicament, and ideal effect does not all appear in treatment.
Cut open inspection pathological changes: after cuing open inspection, Intestinum Sus domestica wall is poor, especially small intestinal rear end and colon position, intestinal mucosa comes off, intestinal wall hyperemia, hemorrhage.
Laboratory diagnosis: get pathologic liver and dye sheet, Gram’s staining, micro-Microscopic observation, the gram negative bacilli of red color visible; Tentatively be judged as bacillus coli.Cultivate by escherichia coli, biochemical test is differentiated, judges that Infection in Piglets is bacillus coli, and pcr amplification proves to produce the ESBLs drug resistant gene and the fosA3 drug resistant gene that have CTX-M type.
Test therapeutic regimen: morbidity swinery is divided 6 groups of administrations, use compound medicine 13 according to the addition administration of 0.3g/kg feedstuff for first group, use compound medicine 14 according to the addition administration of 0.3g/kg feedstuff for second group, use compound medicine 15 according to the addition administration of 3g/kg feedstuff for the 3rd group, use compound medicine 16 according to the addition administration of 1g/kg feedstuff for the 4th group; The 5th group with LIJUNJING powder according to the addition administration of 0.2g/kg feedstuff, the 6th group with the thick powder of Herba speranskiae tuberculatae according to the addition administration of 2.8g/kg feedstuff; Above six groups of therapeutic regimens all continue to use 5 days.
Result of use feedback: first group to the 4th group medication is after 2 days, and swinery is no longer drawn watery stools, feces is shaped, and no longer contains feedstuff in feces, continues to use 3 days swinery recovery from illness; The 5th group of medication is after 2 days, and swinery is still unhealthy, continues to use 3 days, substantially get well, but still draw pasty state feces individually, but drug withdrawal is after 3 days, and recurrence appears in swinery; The 6th group of medication is after 2 days, and swinery, without remarkable improvement, continues to use 3 days, and swinery continues to have loose bowels, and all the other are also more serious individually.Visible, the compound medicine that contains Herba speranskiae tuberculatae is better than folk prescription LIJUNJING and folk prescription Herba speranskiae tuberculatae to swinery curative effect.
5, the efficacy experiment of the piglet diarrhea of the compound medicine product of compound medicine 17-20 gained to 50 ages in days
Clinical symptoms: pig farm, Guigang, Guangxi, 50 age in days piglets, this swinery after wean is turn-taked, starts to occur diarrhoea, draws watery stools, feces contains indigested feedstuff, pig material feeding but be exactly not grow, indivedual serious diarrhea of pigs dehydrations are dead, do not occur symptoms of emesis, raiser uses multi-medicament, and ideal effect does not all appear in treatment.
Cut open inspection pathological changes: after cuing open inspection, Intestinum Sus domestica wall is poor, especially small intestinal rear end and colon position, intestinal mucosa comes off, intestinal wall hyperemia, hemorrhage.
Laboratory diagnosis: get pathologic liver and dye sheet, Gram’s staining, micro-Microscopic observation, the gram negative bacilli of red color visible; Tentatively be judged as bacillus coli.Cultivate by escherichia coli, biochemical test is differentiated, judges that Infection in Piglets is bacillus coli, and pcr amplification proves to produce the ESBLs drug resistant gene and the fosA3 drug resistant gene that have OXA type.
Test therapeutic regimen: morbidity swinery is divided 6 groups of administrations, use compound medicine 17 according to the addition administration of 3g/kg feedstuff for first group, use compound medicine 18 according to the addition administration of 4g/kg feedstuff for second group, use compound medicine 19 according to the addition administration of 7g/kg feedstuff for the 3rd group, use compound medicine 20 according to the addition administration of 2g/kg feedstuff for the 4th group; The 5th group with florfenicol powder according to the addition administration of 0.35g/kg feedstuff, the 6th group with the thick powder of Herba speranskiae tuberculatae according to the addition administration of 3.5g/kg feedstuff; Above six groups of therapeutic regimens all continue to use 5 days.
Result of use feedback: first group to the 4th group medication is after 2 days, and swinery is no longer drawn watery stools, feces is shaped, and no longer contains feedstuff in feces, continues to use 3 days swinery recovery from illness; The 5th group of medication is after 2 days, and swinery is still unhealthy, continues to use 3 days, substantially get well, but still draw pasty state feces individually, but drug withdrawal is after 3 days, and recurrence appears in swinery; The 6th group of medication is after 2 days, and swinery, without remarkable improvement, continues to use 3 days, and swinery continues to have loose bowels, and all the other are also more serious individually.Visible, the compound medicine that contains Herba speranskiae tuberculatae is better than folk prescription florfenicol and folk prescription Herba speranskiae tuberculatae to swinery curative effect.
Claims (11)
1. treat the method for poultry coli-infection disease for one kind, it is characterized in that, Herba speranskiae tuberculatae is mixed according to the part by weight of 3-30:5-200 with the antimicrobial drug for the treatment of poultry coli-infection, obtain the compound medicine containing Herba speranskiae tuberculatae, this compound medicine is added in animal and fowl fodder and fed according to the addition of 0.1-7g/kg feedstuff, use continuously 3-7 days.
2. the method for the treatment of poultry coli-infection disease according to claim 1, it is characterized in that, described antimicrobial drug is the one in beta-lactam antimicrobial drug, fluoroquinolone antibacterial agent, aminoglycoside antimicrobial drug, carbadox class antimicrobial drug, polypeptide class antimicrobial drug, amide alcohols antimicrobial drug or valnemulin hydrochloride.
3. the method for the treatment of poultry coli-infection disease according to claim 2, it is characterized in that, described beta-lactam antimicrobial drug is amoxicillin, fluoroquinolone antibacterial agent is norfloxacin, aminoglycoside antimicrobial drug is amikacin, carbadox class antimicrobial drug is LIJUNJING, and amide alcohols is florfenicol, and polypeptide class is colistin.
4. the method for the treatment of poultry coli-infection disease according to claim 3, is characterized in that, compound medicine is made up of the raw material of following weight ratio: amoxicillin 3-20 part, Herba speranskiae tuberculatae 40-180 part.
5. the method for the treatment of poultry coli-infection disease according to claim 3, is characterized in that, compound medicine is made up of the raw material of following weight ratio: norfloxacin 3-25 part, Herba speranskiae tuberculatae 30-190 part.
6. the method for the treatment of poultry coli-infection disease according to claim 3, is characterized in that, compound medicine is made up of the raw material of following weight ratio: amikacin 5-30 part, Herba speranskiae tuberculatae 10-160 part.
7. the method for the treatment of poultry coli-infection disease according to claim 3, is characterized in that, compound medicine is made up of the raw material of following weight ratio: LIJUNJING 3-20 part, Herba speranskiae tuberculatae 10-180 part.
8. the method for the treatment of poultry coli-infection disease according to claim 3, is characterized in that, compound medicine is made up of the raw material of following weight ratio: colistin 3-30 part, Herba speranskiae tuberculatae 15-170 part.
9. the method for the treatment of poultry coli-infection disease according to claim 3, is characterized in that, compound medicine is made up of the raw material of following weight ratio: florfenicol 5-30 part, Herba speranskiae tuberculatae 10-170 part.
10. the method for the treatment of poultry coli-infection disease according to claim 3, is characterized in that, compound medicine is made up of the raw material of following weight ratio: valnemulin hydrochloride 7-30 part, Herba speranskiae tuberculatae 10-170 part.
The method of 11. treatment poultry coli-infection diseases according to claim 3, is characterized in that, described compound medicine is prepared into powder, tablet, oral liquid or granule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410150094.0A CN103933109A (en) | 2014-04-15 | 2014-04-15 | Method for treating animal escherichia coli infected diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410150094.0A CN103933109A (en) | 2014-04-15 | 2014-04-15 | Method for treating animal escherichia coli infected diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103933109A true CN103933109A (en) | 2014-07-23 |
Family
ID=51181166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410150094.0A Pending CN103933109A (en) | 2014-04-15 | 2014-04-15 | Method for treating animal escherichia coli infected diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103933109A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104436160A (en) * | 2014-11-07 | 2015-03-25 | 广西大学 | Balsamiferou blumea herb and colistin containing compound medicine for livestock and poultry |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103127507A (en) * | 2013-03-18 | 2013-06-05 | 广西大学 | Holly bark containing compound composition for treating escherichia coli infected diseases of livestock and poultry |
| CN103127508A (en) * | 2013-03-18 | 2013-06-05 | 广西大学 | Herba lycopi containing compound composition for treating escherichia coli infected diseases of livestock and poultry |
| CN103146802A (en) * | 2013-03-18 | 2013-06-12 | 广西大学 | Method for screening traditional Chinese medicines influencing drug resistance of escherichia coil generating ESBLs (extended spectyum beta lactamase) |
-
2014
- 2014-04-15 CN CN201410150094.0A patent/CN103933109A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103127507A (en) * | 2013-03-18 | 2013-06-05 | 广西大学 | Holly bark containing compound composition for treating escherichia coli infected diseases of livestock and poultry |
| CN103127508A (en) * | 2013-03-18 | 2013-06-05 | 广西大学 | Herba lycopi containing compound composition for treating escherichia coli infected diseases of livestock and poultry |
| CN103146802A (en) * | 2013-03-18 | 2013-06-12 | 广西大学 | Method for screening traditional Chinese medicines influencing drug resistance of escherichia coil generating ESBLs (extended spectyum beta lactamase) |
Non-Patent Citations (4)
| Title |
|---|
| 张传津等: ""6种中药提取物消除大肠杆菌耐药性的研究"", 《山东畜牧兽医》 * |
| 王思芦等: ""中药消除致病性大肠杆菌耐药性研究进展"", 《中国畜牧兽医》 * |
| 王芳等: ""透骨草提取物的抑菌效果研究"", 《辽宁中医杂志》 * |
| 王静，张淑文: ""中药逆转细菌耐药的研究进展"", 《临床和实验医学杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104436160A (en) * | 2014-11-07 | 2015-03-25 | 广西大学 | Balsamiferou blumea herb and colistin containing compound medicine for livestock and poultry |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103690952B (en) | The compound medicine for the treatment of poultry coli-infection disease | |
| CN103127507B (en) | A kind of compound containing Cortex Ilicis Rotundae treatment poultry coli-infection disease | |
| CN103989728A (en) | Acalypha australis L. and beta-lactam antibacterial medicine containing compound medicine for livestock and poultry | |
| CN103933086A (en) | Creat/amikacin-containing compound medicine for livestock and fowl | |
| CN103948930A (en) | Red paeonia/beta-lactam-antibacterial-agent-containing compound medicine for livestock and fowl | |
| CN103989725A (en) | Acalypha australis L. and amikacin containing compound medicine for livestock and poultry | |
| CN103127508B (en) | Herba lycopi containing compound composition for treating escherichia coli infected diseases of livestock and poultry | |
| CN103961421A (en) | Compound medicine containing radix paeoniae rubra and mequindox for livestock and poultry | |
| CN103961400A (en) | Compound medicine comprising herba lycopi and florfenicol and used for livestock and poultry | |
| CN103977088A (en) | Compound medicine containing radix paeoniae rubrathe and fluoroquinolones antibacterial drug used for livestock and poultry | |
| CN103948656A (en) | Creat/fosfomycin-containing compound medicine for livestock and fowl | |
| CN103301463A (en) | Compound composition containing plumbago zeylanica for treating livestock and poultry escherichia coli infection diseases | |
| CN103948692A (en) | Red paeonia/amikacin-containing compound medicine for livestock and fowl | |
| CN103908670B (en) | A kind of compound treating poultry coli-infection disease | |
| CN104027369A (en) | Plumbago zeylanica and norfloxacin containing compound composition for livestock and poultry | |
| CN103948677A (en) | Boneset/amoxicillin-containing compound medicine for livestock and fowl | |
| CN103933544B (en) | A kind of poultry compound medicine containing Herba Andrographis and colistin | |
| CN103961401A (en) | Compound medicine comprising herba lycopi and sulfamonomethoxine sodium and used for livestock and poultry | |
| CN103933543B (en) | Utilize the method for Herba Andrographis and colistin treatment poultry coli-infection disease | |
| CN104367601A (en) | Compound medicine containing herba pteridis multifidae and mequindox for livestock and poultry | |
| CN104436160A (en) | Balsamiferou blumea herb and colistin containing compound medicine for livestock and poultry | |
| CN103933109A (en) | Method for treating animal escherichia coli infected diseases | |
| CN104435013A (en) | Pteris multifida and amikacin-containing compound drug for livestock and poultry | |
| CN104306422A (en) | Balsamiferou Blumea herb and beta-lactam antibacterial drug containing compound medicine for livestock and poultry | |
| CN104027370A (en) | Plumbago zeylanica and mequindox containing compound composition for livestock and poultry |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140723 |